Lantheus’s subsidiary Exini Diagnostics and the Prostate Cancer Clinical Trial Consortium (PCCTC) have teamed up to advance new artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer.
In specific clinical studies, the prostate cancer AI platform from Lantheus will be used to help measure the imaging response in prostate cancer patients.
The platform comprises US Food and Drug Administration (FDA) and CE cleared medical devices for bone scintigraphy (aBSI) and PSMA PET/CT (aPROMISE).
aPROMISE is a vendor-neutral stand-alone software as a medical device that is designed to quantify PSMA PET/CT in prostate cancer and received FDA clearance last year.
The aBSI product is developed to calculate the automated bone scan index in Technetium-99m bone scintigraphy of patients with prostate cancer. It received FDA clearance in 2019.
The new collaboration is aimed at integrating the AI platform into PCCTC’s early phase clinical research for the advancement of the new AI-enabled biomarkers’ discovery, development and validation.
Content from our partners
Lantheus noted that these biomarkers have the potential to play an important role in identifying patients as well as evaluating the response of targeted treatments.
The company’s AI platform can also improve the utility of data generation from different imaging tools, such as PSMA PET/CT, bone scintigraphy, MRI and CT, which are used in prostate cancer.
Lantheus chief business officer Etienne Montagut said: “Lantheus believes its AI platform can expand the utility of imaging diagnostics for precision medicine in prostate cancer and evolve from single biomarker image analysis to an integrated clinical decision support system drawing on multiple biomarkers and clinical record data.”
In 2020, the company received US FDA approval for its supplemental new drug application (sNDA) for VIALMIXRFID and DEFINITY.
Related Companies
